BACKGROUND AND METHODS Silica-coated magnetic nanoparticle (SiO(2)-MNP) prepared by the sol-gel method was studied as a nanocarrier for targeted delivery of tissue plasminogen activator (tPA). The nanocarrier consists of a superparamagnetic iron oxide core and an SiO(2) shell and is characterized by transmission electron microscopy, Fourier transform infrared spectroscopy, X-ray diffraction, su...

BACKGROUND AND PURPOSE Microthrombi originating from disintegrated clots or formed in situ may account for the poor clinical improvement of acute ischemic stroke after recanalization therapy. We attempted to determine whether microbubble-mediated sonothrombolysis could dissolve platelet-rich and erythrocyte-rich microthrombi, thereby reducing their brain injury-causing potential. METHODS Plat...

BACKGROUND The duration of cerebral blood flow impairment correlates with irreversibility of brain damage in animal models of cerebral ischemia. Our aim was to correlate clinical recovery from stroke with the timing of arterial recanalization after therapy with intravenous tissue plasminogen activator (tPA). METHODS Patients with symptoms of cerebral ischemia were treated with 0.9 mg/kg tPA I...

In this issue of the journal, Liu et al. described how they developed gelatin-coated Dacron to locally deliver the tissue-type plasminogen activator (tPA) plasmid for preventing thrombosis. In the traditional clinical treatment for thrombotic diseases, tPAs are widely used to induce plasmin formation, which degrades fibrin in blood clots and restores vascular flow. 1-3 Vascular flow is restored...

BACKGROUND AND PURPOSE Intravenous recombinant tissue plasminogen activator (tPA) at a dose of 0.9 mg/kg body weight is associated with a high hemorrhagic transformation (HT) rate. Low-dose tPA (0.6 mg/kg) may have a lower hemorrhage rate but the mortality and disability rates at 90 days cannot be confirmed as non-inferior to standard-dose tPA. Whether the doses 0.7 and 0.8 mg/kg have better ef...

t has been now 20 years since the publication of the National Institute of Neurological Disorders and Stroke (NINDS) tissue type plasminogen activator (tPA) trial. 1 This randomized controlled trial initiated a paradigm shift in the management of ischemic stroke. Before 1995, it was standard for patients with stroke to languish in emergency departments with no need to perform urgent brain imagi...

thrombolysis for stroke is being used in some developing countries. this study was designed to evaluate the problems of thrombolysis therapy in iran. during january-july 2008, all patients with ischemic stroke admitted to ghaem hospital, mashhad, northeast iran, were enrolled in a prospective observational study. ghaem hospital is a tertiary care hospital that includes infrastructure for thromb...

Although different hypotheses have been formulated to explain schizophrenia pathogenesis, the links between them are weak. The observation that five psychotic patients on chronic warfarin therapy for deep-vein thrombosis showed long-term remission of psychotic symptoms made us suspect that abnormalities in the coagulation pathway, specifically low tissue plasminogen activator (tPA) activity, co...

Achieving early, complete, and sustained reperfusion after acute myocardial infarction does not occur in approximately 50% of patients, even with the most potent established thrombolytic therapy. Bleeding is observed with increased concentrations of thrombolytics as well as with adjunctive antithrombotic and antiplatelet agents. A novel approach to enhance thrombolytic therapy is to inhibit the...